Unusual Presentation of Lung Adenocarcinoma With Paraneoplastic Stiff Person Syndrome: Role of EGFR Tyrosine Kinase Inhibitors.

Suppr

超能文献

作者信息

Sarwari Nawid, Galili Yehuda, Perez Ariel, Avgeropoulos Nicholas, Tseng Jennifer

机构信息

UF Health Cancer Center, Orlando, Florida.

Internal Medicine Department, Orlando Regional Medical Center, Orlando, Florida.

出版信息

J Thorac Oncol. 2019 Aug;14(8):e179-e180. doi: 10.1016/j.jtho.2019.03.025.

DOI:10.1016/j.jtho.2019.03.025

PMID:31345344

Abstract

摘要

相似文献

Unusual Presentation of Lung Adenocarcinoma With Paraneoplastic Stiff Person Syndrome: Role of EGFR Tyrosine Kinase Inhibitors.

J Thorac Oncol. 2019 Aug;14(8):e179-e180. doi: 10.1016/j.jtho.2019.03.025.

Hepatoid Adenocarcinoma of the Lung with EGFR Mutation and the Response to Tyrosine Kinase Inhibitors.伴有表皮生长因子受体（EGFR）突变的肺肝样腺癌及其对酪氨酸激酶抑制剂的反应

J Thorac Oncol. 2019 Oct;14(10):e217-e219. doi: 10.1016/j.jtho.2019.04.032.

Tyrosine Kinase Inhibition in a Lung Adenocarcinoma Patient With Dual G719S and S768I EGFR Mutations.一名具有G719S和S768I双重表皮生长因子受体（EGFR）突变的肺腺癌患者的酪氨酸激酶抑制作用

J Thorac Oncol. 2018 Aug;13(8):e136-e137. doi: 10.1016/j.jtho.2018.03.021.

[Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].[晚期肺腺癌患者血浆中表皮生长因子受体突变的相对丰度预测对表皮生长因子受体-酪氨酸激酶抑制剂的临床反应]

Zhonghua Nei Ke Za Zhi. 2019 Jan 1;58(1):49-55. doi: 10.3760/cma.j.issn.0578-1426.2019.01.009.

Pseudoprogression and Rapid Response to Pembrolizumab in a Patient with Advanced Lung Adenocarcinoma with Loss of Epidermal Growth Factor Receptor Gene Mutation after Tyrosine Kinase Inhibitor Therapy.一名晚期肺腺癌患者在酪氨酸激酶抑制剂治疗后表皮生长因子受体基因突变缺失，出现假性进展并对帕博利珠单抗快速反应

J Thorac Oncol. 2018 Oct;13(10):e209-e210. doi: 10.1016/j.jtho.2018.05.021.

A case of EGFR mutation-positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment.1例经反复EGFR-TKI治疗后T790M等位基因分数升高的EGFR突变阳性肺腺癌病例。

Cancer Commun (Lond). 2019 Nov 1;39(1):67. doi: 10.1186/s40880-019-0413-5.

Comparative effectiveness of concurrent chemoradiotherapy versus EGFR-tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR.比较伴化疗同期与 EGFR 酪氨酸激酶抑制剂治疗携带突变型 EGFR 的 IIIb 期肺腺癌患者的疗效。

Thorac Cancer. 2018 Nov;9(11):1398-1405. doi: 10.1111/1759-7714.12847. Epub 2018 Aug 27.

A Case of Novel Inversion Mutation of EGFR Exon 19 Leading to Primary Resistance to EGFR TKIs in Lung Adenocarcinoma.一例表皮生长因子受体（EGFR）第19外显子新型倒位突变导致肺腺癌对EGFR酪氨酸激酶抑制剂原发性耐药的病例

J Thorac Oncol. 2018 Jun;13(6):e97-e101. doi: 10.1016/j.jtho.2017.12.014. Epub 2018 Feb 28.

The KIF5B-RET Fusion Gene Mutation as a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma.KIF5B-RET融合基因突变作为肺腺癌获得性表皮生长因子受体酪氨酸激酶抑制剂耐药的新机制

Clin Lung Cancer. 2019 Jan;20(1):e73-e76. doi: 10.1016/j.cllc.2018.09.011. Epub 2018 Sep 21.

Combination Treatment Using an EGFR Tyrosine Kinase Inhibitor plus Platinum-Based Chemotherapy for a Patient with Transformed Small Cell Carcinoma and EGFR-Mutated Lung Adenocarcinoma.表皮生长因子受体酪氨酸激酶抑制剂联合铂类化疗治疗转化型小细胞癌合并表皮生长因子受体突变肺腺癌患者

J Thorac Oncol. 2017 Dec;12(12):e199-e200. doi: 10.1016/j.jtho.2017.07.034.

引用本文的文献

An update on malignant tumor-related stiff person syndrome spectrum disorders: clinical mechanism, treatment, and outcomes.恶性肿瘤相关僵人综合征谱系障碍的最新进展：临床机制、治疗及预后

Front Neurol. 2023 Oct 4;14:1209302. doi: 10.3389/fneur.2023.1209302. eCollection 2023.

Glutamic acid decarboxylase (GAD) antibody-positive paraneoplastic stiff person syndrome associated with mediastinal liposarcoma.谷氨酸脱羧酶（GAD）抗体阳性副肿瘤性僵人综合征伴纵隔脂肪肉瘤。

BMJ Case Rep. 2022 Jul 7;15(7):e250639. doi: 10.1136/bcr-2022-250639.

Stiff-Person Syndrome: Seeing Past Comorbidities to Reach the Correct Diagnosis.僵人综合征：透过合并症准确诊断

Case Rep Neurol Med. 2021 Jan 31;2021:6698046. doi: 10.1155/2021/6698046. eCollection 2021.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验